Back to all Programs

Register here

Related Materials

Past event

International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019

Viral Hepatitis and Liver Disease

50% Adherence is Enough with Modern ARVs, Right? - Terrence Blaschke

Viral Hepatitis and Liver Disease

The "Third Wave" of TB Drug Development: What's on the Horizon - Kelly Dooley

Viral Hepatitis and Liver Disease

Novel Antiviral and Immune Targets to Cure HBV - Fabien Zoulim

Viral Hepatitis and Liver Disease

Pharmacological Treatment of NASH - Sven Francque

Viral Hepatitis and Liver Disease

Improved Long-Acting Drug Delivery: What are the Technologies? - Andrew Owen

Viral Hepatitis and Liver Disease

Long-Acting HIV Drugs for Treatment: Data and Potential Implementation - Charles Flexner

Viral Hepatitis and Liver Disease

Long-Acting HIV Drugs for Treatment: Data and Potential Implementation - Laura Waters

Viral Hepatitis and Liver Disease

Clinical Case Presentation - Catia Marzolini

Viral Hepatitis and Liver Disease

Dual Maintenance for HIV: Why Fix it if it's not Broken? (Debate: Con) - Andrew Hill

Viral Hepatitis and Liver Disease

Dual Maintenance for HIV: Why Fix it if it's not Broken? (Debate: Pro) - Jose Arribas

Viral Hepatitis and Liver Disease

Dual Maintenance for HIV: Why Fix it if it's not Broken? (Debate: Discussion)

Viral Hepatitis and Liver Disease

CRISPR/Cas and Gene Editing for HIV - Paula Cannon